Boundless Bio, Inc.

Boundless Bio, Inc. (BOLD) priced its initial public offering on Mar 28, 2024 at $16.00 per share, within its $15.00–$17.00 range, raising $100M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $355.8M. Goldman Sachs was lead-left underwriter, joined by Leerink Partners, Piper Sandler and Guggenheim. Latham & Watkins advised the company and Cooley advised the underwriters.

Boundless Bio, Inc. is a clinical-stage oncology company developing therapies for patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA). It uses its Spyglass platform to identify targets essential for ecDNA-driven cancers.

Status

IPO

Ticker

BOLD

Exchange

Nasdaq Global Select

Priced

Mar 28, 2024

IPO price

$16.00

Price range

$15.00–$17.00

Raised

$100M

Market cap at IPO price

$355.8M

First filed

Mar 6, 2024

Underwriters

Goldman Sachs, Leerink Partners, Piper Sandler and Guggenheim

Company counsel

Latham & Watkins

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.